7 December 2020 - The pharmaceutical company offered the government a chance to lock in additional supplies before its vaccine was proved effective in clinical trials.

Before Pfizer’s coronavirus vaccine was proved highly successful in clinical trials last month, the company offered the Trump administration the chance to lock in supplies beyond the 100 million doses the pharmaceutical maker agreed to sell the government as part of a $1.95 billion deal over the summer.

Read New York Times article